Tag: GlobeNewswire

Presentations reinforce Zscaler’s growth plans and its position as the cybersecurity platform for the AI era

SANTA CLARA, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) — Zscaler, Inc. (Nasdaq: ZS), the cybersecurity platform for the AI era, is hosting its 2026 Investor Day today in New York City. In conjunction with its Investor Day, Zscaler reaffirmed its financial guidance for the first quarter and full fiscal year 2027.

“As AI forces every enterprise to rethink their approach to security, the value of our Zero Trust architecture is becoming increasingly clear,” said Jay Chaudhry, CEO, Chairman, and Founder of Zscaler. “The agentic AI era is quickly becoming the most significant opportunity in our company’s history. Our Zero Trust platform was purpose-built to solve the challenges customers face today – protecting against AI-driven threats, securing data everywhere, and enabling the secure deployment of AI – by hiding the attack surface and preventing lateral movement. Backed by a powerful customer growth flywheel, we have multiple growth engines that we believe will enable us to capitalize on AI tailwinds and drive Zscaler towards achieving our $10 billion ARR target.”

At its Investor Day, Zscaler executives will discuss the company’s strategy, platform innovation, go-to-market priorities, and long-term growth drivers. Featured Zscaler executives include:

• Jay Chaudhry, CEO, Chairman, and Founder
• Kevin Rubin, Chief Financial Officer
• Adam Geller, Chief Product Officer
• Ross Tackett, Chief Revenue Officer
• Dhawal Sharma, Executive Vice President, AI & Data Security

Reaffirms First Quarter and Full year Fiscal 2027 Guidance

Zscaler reaffirmed its first quarter and full year fiscal 2027 guidance, previously provided on Sept. 3, 2026. For the first quarter of fiscal 2027, the company expects:

• Revenue of $935 million to $939 million, approximately 19% year-over-year growth.
• Non-GAAP gross margin of approximately 80%
• Non-GAAP income from operations of $215 million to $217 million, approximately 25% to 26% year-over-year growth, representing a 23% operating margin.
• Non-GAAP net income per share of approximately $1.15 to $1.16, assuming approximately 170 million fully diluted shares outstanding and a non-GAAP tax rate of 21%.

For the full year fiscal 2027, the company expects:

• ARR of $4.396 billion to $4.426 billion, growth of approximately 16.6% to 17.4%.
• Revenue of approximately $3.908 billion to $3.938 billion, growth of 16.6% to 17.5%.
• Non-GAAP gross margin of approximately 80%
• Non-GAAP income from operations of $924 million to $932 million, growth of approximately 21%.
• Non-GAAP net income per share of $4.86 to $4.90, assuming approximately 173 million fully diluted shares outstanding and a non-GAAP tax rate of 21%.
• Free cash flow margin of approximately 23.0 to 23.5%.

Guidance for non-GAAP income from operations and non-GAAP net income per share exclude, as applicable, stock-based compensation expense and related employer payroll taxes, amortization expense of acquired intangible assets and amortization of debt issuance costs. We have not reconciled our expectations of non-GAAP income from operations and non-GAAP net income per share to their most directly comparable GAAP measures because certain items are out of our control or cannot be reasonably predicted. For those reasons, we are also unable to address the probable significance of the unavailable information, the variability of which may have a significant impact on future results. Accordingly, a reconciliation for the guidance for non-GAAP income from operations and non-GAAP net income per share is not available without unreasonable effort.

Investor Day: How to Participate

The half-day event can be viewed live at https://ir.zscaler.com/events/event-details/zscaler-investor-day-2026. A replay will be available on Zscaler’s Investor Relations website shortly after the event ends.

Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties, including, but not limited to, statements regarding our ability to capture opportunities related to AI and our future financial and operating performance, including our financial outlook for the first quarter of fiscal 2027 and full year fiscal 2027. There are a significant number of factors that could cause actual results to differ materially from statements made in this press release, including but not limited to: macroeconomic influences and instability, geopolitical events, operations and financial results and the economy in general; risks related to the use of AI in our platform; our ability to identify and effectively implement the necessary changes to address execution challenges; risks associated with managing our rapid growth, including fluctuations from period to period; our limited experience with new products and subscription and support introductions and the risks associated with new products and subscription and support offerings, including the discovery of software bugs; our ability to attract and retain new customers; the failure to timely develop and achieve market acceptance of new products and subscriptions as well as existing products and subscriptions and support; rapidly evolving technological developments in the market for network security products and subscription and support offerings and our ability to remain competitive; length of sales cycles; useful lives of our assets and other estimates; and general market, political, economic and business conditions.

Additional risks and uncertainties that could affect our financial results are included under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” set forth from time to time in our filings and reports with the Securities and Exchange Commission (“SEC”), including our Annual Report on Form 10-K for the fiscal year ended July 31, 2026, filed on September 3, 2026, as well as future filings and reports by us, copies of which are available on our website at ir.zscaler.com and on the SEC’s website at www.sec.gov. You should not rely on these forward-looking statements, as actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of such risks and uncertainties. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.

About Zscaler
Zscaler (NASDAQ: ZS) is the pioneer and global leader in zero trust security and the cybersecurity platform for the AI era. The world’s largest businesses, critical infrastructure organizations, and government agencies rely on the Zscaler Zero Trust Exchange™ to secure their users, devices, workloads, and AI agents, protect their data, and safely adopt AI, all on one unified platform. Distributed across 200+ data centers and inspecting more than 750 billion transactions a day, Zscaler blocks billions of threats while reducing cost and complexity for the modern enterprise.

Investor Relations Contacts

Kim Watkins
SVP, Investor Relations & Strategic Finance
ir@zscaler.com

Nick Gonzalez
Director, Media Relations
press@zscaler.com

Presentations reinforce Zscaler’s growth plans and its position as the cybersecurity platform for the AI era

SANTA CLARA, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) — Zscaler, Inc. (Nasdaq: ZS), the cybersecurity platform for the AI era, is hosting its 2026 Investor Day today in New York City. In conjunction with its Investor Day, Zscaler reaffirmed its financial guidance for the first quarter and full fiscal year 2027.

“As AI forces every enterprise to rethink their approach to security, the value of our Zero Trust architecture is becoming increasingly clear,” said Jay Chaudhry, CEO, Chairman, and Founder of Zscaler. “The agentic AI era is quickly becoming the most significant opportunity in our company’s history. Our Zero Trust platform was purpose-built to solve the challenges customers face today – protecting against AI-driven threats, securing data everywhere, and enabling the secure deployment of AI – by hiding the attack surface and preventing lateral movement. Backed by a powerful customer growth flywheel, we have multiple growth engines that we believe will enable us to capitalize on AI tailwinds and drive Zscaler towards achieving our $10 billion ARR target.”

At its Investor Day, Zscaler executives will discuss the company’s strategy, platform innovation, go-to-market priorities, and long-term growth drivers. Featured Zscaler executives include:

• Jay Chaudhry, CEO, Chairman, and Founder
• Kevin Rubin, Chief Financial Officer
• Adam Geller, Chief Product Officer
• Ross Tackett, Chief Revenue Officer
• Dhawal Sharma, Executive Vice President, AI & Data Security

Reaffirms First Quarter and Full year Fiscal 2027 Guidance

Zscaler reaffirmed its first quarter and full year fiscal 2027 guidance, previously provided on Sept. 3, 2026. For the first quarter of fiscal 2027, the company expects:

• Revenue of $935 million to $939 million, approximately 19% year-over-year growth.
• Non-GAAP gross margin of approximately 80%
• Non-GAAP income from operations of $215 million to $217 million, approximately 25% to 26% year-over-year growth, representing a 23% operating margin.
• Non-GAAP net income per share of approximately $1.15 to $1.16, assuming approximately 170 million fully diluted shares outstanding and a non-GAAP tax rate of 21%.

For the full year fiscal 2027, the company expects:

• ARR of $4.396 billion to $4.426 billion, growth of approximately 16.6% to 17.4%.
• Revenue of approximately $3.908 billion to $3.938 billion, growth of 16.6% to 17.5%.
• Non-GAAP gross margin of approximately 80%
• Non-GAAP income from operations of $924 million to $932 million, growth of approximately 21%.
• Non-GAAP net income per share of $4.86 to $4.90, assuming approximately 173 million fully diluted shares outstanding and a non-GAAP tax rate of 21%.
• Free cash flow margin of approximately 23.0 to 23.5%.

Guidance for non-GAAP income from operations and non-GAAP net income per share exclude, as applicable, stock-based compensation expense and related employer payroll taxes, amortization expense of acquired intangible assets and amortization of debt issuance costs. We have not reconciled our expectations of non-GAAP income from operations and non-GAAP net income per share to their most directly comparable GAAP measures because certain items are out of our control or cannot be reasonably predicted. For those reasons, we are also unable to address the probable significance of the unavailable information, the variability of which may have a significant impact on future results. Accordingly, a reconciliation for the guidance for non-GAAP income from operations and non-GAAP net income per share is not available without unreasonable effort.

Investor Day: How to Participate

The half-day event can be viewed live at https://ir.zscaler.com/events/event-details/zscaler-investor-day-2026. A replay will be available on Zscaler’s Investor Relations website shortly after the event ends.

Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties, including, but not limited to, statements regarding our ability to capture opportunities related to AI and our future financial and operating performance, including our financial outlook for the first quarter of fiscal 2027 and full year fiscal 2027. There are a significant number of factors that could cause actual results to differ materially from statements made in this press release, including but not limited to: macroeconomic influences and instability, geopolitical events, operations and financial results and the economy in general; risks related to the use of AI in our platform; our ability to identify and effectively implement the necessary changes to address execution challenges; risks associated with managing our rapid growth, including fluctuations from period to period; our limited experience with new products and subscription and support introductions and the risks associated with new products and subscription and support offerings, including the discovery of software bugs; our ability to attract and retain new customers; the failure to timely develop and achieve market acceptance of new products and subscriptions as well as existing products and subscriptions and support; rapidly evolving technological developments in the market for network security products and subscription and support offerings and our ability to remain competitive; length of sales cycles; useful lives of our assets and other estimates; and general market, political, economic and business conditions.

Additional risks and uncertainties that could affect our financial results are included under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” set forth from time to time in our filings and reports with the Securities and Exchange Commission (“SEC”), including our Annual Report on Form 10-K for the fiscal year ended July 31, 2026, filed on September 3, 2026, as well as future filings and reports by us, copies of which are available on our website at ir.zscaler.com and on the SEC’s website at www.sec.gov. You should not rely on these forward-looking statements, as actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of such risks and uncertainties. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.

About Zscaler
Zscaler (NASDAQ: ZS) is the pioneer and global leader in zero trust security and the cybersecurity platform for the AI era. The world’s largest businesses, critical infrastructure organizations, and government agencies rely on the Zscaler Zero Trust Exchange™ to secure their users, devices, workloads, and AI agents, protect their data, and safely adopt AI, all on one unified platform. Distributed across 200+ data centers and inspecting more than 750 billion transactions a day, Zscaler blocks billions of threats while reducing cost and complexity for the modern enterprise.

Investor Relations Contacts

Kim Watkins
SVP, Investor Relations & Strategic Finance
ir@zscaler.com

Nick Gonzalez
Director, Media Relations
press@zscaler.com

Utrecht, 6 October 2026

Aalberts today reports that it has repurchased 81,500 of its own shares in the period from 28 September 2026, up to and including 2 October 2026 for an amount of EUR 3,497,956.70 so at an average share price of EUR 42.92.

This is part of the share buyback programme as announced on 26 February 2026, for a total amount of EUR 75 million. The repurchase of shares commenced on 27 February 2026 and will be completed no later than 9 October 2026. It is intended that the shares will be cancelled following repurchase.

Up to and including 2 October 2026, a cumulative total of 1,984,211 shares was repurchased under the share buyback programme for a total consideration of EUR 71,405,943.

Aalberts has engaged an intermediary to repurchase the Aalberts shares in the open market, during open and closed periods, independent of Aalberts.

The share buyback will be executed within the limitations of the authority granted by the Annual General Meeting (AGM) on April 10, 2025. The programme will be conducted within the parameters prescribed by the Market Abuse Regulation 596/2014 and the safe harbour parameters prescribed by the Commission Delegated Regulation 2016/1052 for share buybacks.

Visit aalberts.com/sbb for the weekly progress overview.

Attachment

• Press release

Utrecht, 6 October 2026

Aalberts today reports that it has repurchased 81,500 of its own shares in the period from 28 September 2026, up to and including 2 October 2026 for an amount of EUR 3,497,956.70 so at an average share price of EUR 42.92.

This is part of the share buyback programme as announced on 26 February 2026, for a total amount of EUR 75 million. The repurchase of shares commenced on 27 February 2026 and will be completed no later than 9 October 2026. It is intended that the shares will be cancelled following repurchase.

Up to and including 2 October 2026, a cumulative total of 1,984,211 shares was repurchased under the share buyback programme for a total consideration of EUR 71,405,943.

Aalberts has engaged an intermediary to repurchase the Aalberts shares in the open market, during open and closed periods, independent of Aalberts.

The share buyback will be executed within the limitations of the authority granted by the Annual General Meeting (AGM) on April 10, 2025. The programme will be conducted within the parameters prescribed by the Market Abuse Regulation 596/2014 and the safe harbour parameters prescribed by the Commission Delegated Regulation 2016/1052 for share buybacks.

Visit aalberts.com/sbb for the weekly progress overview.

Attachment

• Press release

Strategic collaboration with leading global contract research organization to implement randomized, double-blind, placebo-controlled Phase 2 study of novel neuroprotective therapy

TORONTO, Oct. 06, 2026 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) (“Quantum BioPharma”), a biopharmaceutical company focused on developing innovative therapies and technologies, today announced that it has entered into a Study Start-Up Agreement (“SUA”) with the clinical research business of Thermo Fisher Scientific to implement Quantum’s Phase 2 clinical trial of Lucid-21-302 (“Lucid-MS”) for multiple sclerosis (“MS”).

The execution of the contract represents an important milestone in the clinical development of Lucid-MS and marks the initiation of formal study start-up activities. Following the Company’s receipt of FDA clearance to proceed with the planned Phase 2 clinical trial, Quantum BioPharma is advancing into implementation.

The PPD™ Clinical Research Business within Thermo Fisher is a leading global contract research organization with extensive experience supporting global clinical development programs across therapeutic areas, including central nervous system (“CNS”) and multiple sclerosis studies.

Under the terms of the contract, Thermo Fisher will support Quantum BioPharma in implementing the Phase 2 clinical trial, including study start-up activities and related clinical research services.

The Phase 2 trial will evaluate the efficacy, safety, and tolerability of Lucid-MS in people with progressive forms of MS. The randomized, double-blind, placebo-controlled study is designed to evaluate clinical and radiological endpoints relevant to disease progression and disease biology.

“We are pleased to enter into a contract with the clinical research business of Thermo Fisher as we advance the Lucid-MS program toward Phase 2,” said Zeeshan Saeed, Chief Executive Officer of Quantum BioPharma. “Following FDA clearance to proceed with the Phase 2 study, initiating study start-up activities with a leading global CRO with extensive CNS and MS experience represents an important next step. We look forward to working with Thermo Fisher, our investigators and clinical research partners as we initiate the Lucid-MS Phase 2 study.”

Andrzej Chruscinski, President, Scientific and Clinical Affairs at Quantum BioPharma, said, “Lucid-MS is designed around a novel neuroprotective approach that targets demyelination rather than solely modulating the immune system. The Phase 2 study will provide an important opportunity to evaluate this approach using clinical and radiological measures. Entering into the Study Start-Up Agreement allows us to begin the operational work required, and we look forward to working closely with Thermo Fisher and our clinical investigators as the program advances.”

“We’re proud to partner with Quantum BioPharma in advancing their neuro-degenerative clinical program in multiple sclerosis,” said Michael Cioffi, Vice President and General Manager, Neuroscience, Clinical Research, Thermo Fisher. “Our team brings deep experience in CNS and MS trials, along with an integrated approach that connects strategy and execution to help deliver these complex studies. By combining scientific expertise with operational excellence, we can help bring promising new therapies closer to the patients who need them.” 

About Lucid-MS (Lucid-21-302)

Lucid-MS is an investigational, first-in-class New Chemical Entity designed to provide neuroprotection through inhibition of demyelination. Quantum BioPharma is developing Lucid-MS as a potential treatment for multiple sclerosis, with a focus on progressive forms of the disease. By targeting protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation, Lucid-MS is being developed as a potential therapeutic approach to address demyelination and neurodegenerative processes associated with MS. In preclinical models, Lucid-MS has demonstrated the ability to prevent and reverse measures of myelin degradation.

Market Opportunity and Growth Strategy

Multiple sclerosis affects approximately 2.8 million people worldwide (source: https://pmc.ncbi.nlm.nih.gov Atlas of MS, Third Edition (PMC/NCBI)), representing a significant global healthcare challenge and substantial market opportunity for innovative treatments. The MS therapeutic market is projected to exceed $38 billion by 2030 according to Grand View Research www.grandviewresearch.com.

Quantum BioPharma’s differentiated approach—targeting demyelination directly—positions Lucid-MS to address current unmet patient needs and potentially capture meaningful market share in the emerging neuroprotective segment.

About Quantum BioPharma Ltd.

Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD™ and spun out its OTC version to Unbuzzd Wellness Inc. (“Unbuzzd”) (formerly, Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.48% (as of June 30, 2026) of Unbuzzd. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

For more information visit www.quantumbiopharma.com.

Forward-Looking Information

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is generally, but not always, identified by words such as “anticipates,” “believes,” “expects,” “intends,” “plans,” “potential,” “proposes,” “estimates,” “may,” “could,” “would,” “will” and similar expressions. Forward-looking information in this news release includes, but is not limited to, statements regarding the planned Phase 2 clinical trial of Lucid-21-302 (“Lucid-MS”) in multiple sclerosis; the initiation, timing, design, conduct, enrollment, execution and completion of the Phase 2 trial; study start-up activities and related clinical research services to be provided by PPD; the Company’s ability to advance Lucid-MS following FDA clearance to proceed with the planned Phase 2 trial; the anticipated evaluation of the efficacy, safety and tolerability of Lucid-MS and of clinical and radiological endpoints; the potential neuroprotective effects, mechanism of action, therapeutic benefits and commercial potential of Lucid-MS; the Company’s ability to work with PPD, investigators and other clinical research partners; and the size, growth and potential opportunities within the multiple sclerosis therapeutics market.

Forward-looking information is based on management’s current expectations, estimates, projections, assumptions and beliefs as of the date of this news release, including assumptions regarding the Company’s ability to successfully complete study start-up activities; obtain and maintain all additional regulatory, ethics committee and institutional approvals or authorizations required to initiate and conduct the Phase 2 trial; identify, activate and retain suitable clinical trial sites and investigators; recruit and retain eligible patients within anticipated timelines; secure sufficient financing and other resources to fund the trial and the continued development of Lucid-MS; maintain adequate supplies of clinical trial material; obtain satisfactory performance from PPD and other third-party service providers; and the accuracy and applicability of preclinical findings, market data and third-party research.

Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking information. These risks and uncertainties include, among others, risks inherent in clinical development, including delays or difficulties in study start-up, site activation, patient recruitment or retention; the possibility that clinical trial results may not demonstrate the safety, efficacy or therapeutic benefit anticipated from preclinical or earlier-stage data; adverse events or other safety findings; changes in trial design, timelines, costs or regulatory requirements; the possibility that regulatory authorities may impose additional requirements, clinical holds or other restrictions; the Company’s dependence on PPD, investigators, clinical sites, manufacturers and other third parties; the availability and cost of capital; the Company’s ability to protect and maintain its intellectual property rights; competition from existing and future therapies; changes in applicable laws and regulations; and general economic, financial market and industry conditions. Drug development is inherently uncertain, and there can be no assurance that Lucid-MS will successfully complete clinical development, receive regulatory approval or, if approved, achieve commercial success.

Although the Company believes that the assumptions and expectations reflected in such forward-looking information are reasonable, there can be no assurance that they will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Actual results and future events could differ materially from those anticipated in such information.

The forward-looking information contained in this news release is made as of the date hereof. Except as required by applicable securities laws, the Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

Contacts:

Investor Relations
Robert Guzman, Investor Relations
Email:Rob@QuantumBioPharma.com
Telephone: (833) 304-0323
General Inquiries:info@QuantumBioPharma.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e240cd5f-4494-4560-80ed-5d2b856a1e14

Strategic collaboration with leading global contract research organization to implement randomized, double-blind, placebo-controlled Phase 2 study of novel neuroprotective therapy

TORONTO, Oct. 06, 2026 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) (“Quantum BioPharma”), a biopharmaceutical company focused on developing innovative therapies and technologies, today announced that it has entered into a Study Start-Up Agreement (“SUA”) with the clinical research business of Thermo Fisher Scientific to implement Quantum’s Phase 2 clinical trial of Lucid-21-302 (“Lucid-MS”) for multiple sclerosis (“MS”).

The execution of the contract represents an important milestone in the clinical development of Lucid-MS and marks the initiation of formal study start-up activities. Following the Company’s receipt of FDA clearance to proceed with the planned Phase 2 clinical trial, Quantum BioPharma is advancing into implementation.

The PPD™ Clinical Research Business within Thermo Fisher is a leading global contract research organization with extensive experience supporting global clinical development programs across therapeutic areas, including central nervous system (“CNS”) and multiple sclerosis studies.

Under the terms of the contract, Thermo Fisher will support Quantum BioPharma in implementing the Phase 2 clinical trial, including study start-up activities and related clinical research services.

The Phase 2 trial will evaluate the efficacy, safety, and tolerability of Lucid-MS in people with progressive forms of MS. The randomized, double-blind, placebo-controlled study is designed to evaluate clinical and radiological endpoints relevant to disease progression and disease biology.

“We are pleased to enter into a contract with the clinical research business of Thermo Fisher as we advance the Lucid-MS program toward Phase 2,” said Zeeshan Saeed, Chief Executive Officer of Quantum BioPharma. “Following FDA clearance to proceed with the Phase 2 study, initiating study start-up activities with a leading global CRO with extensive CNS and MS experience represents an important next step. We look forward to working with Thermo Fisher, our investigators and clinical research partners as we initiate the Lucid-MS Phase 2 study.”

Andrzej Chruscinski, President, Scientific and Clinical Affairs at Quantum BioPharma, said, “Lucid-MS is designed around a novel neuroprotective approach that targets demyelination rather than solely modulating the immune system. The Phase 2 study will provide an important opportunity to evaluate this approach using clinical and radiological measures. Entering into the Study Start-Up Agreement allows us to begin the operational work required, and we look forward to working closely with Thermo Fisher and our clinical investigators as the program advances.”

“We’re proud to partner with Quantum BioPharma in advancing their neuro-degenerative clinical program in multiple sclerosis,” said Michael Cioffi, Vice President and General Manager, Neuroscience, Clinical Research, Thermo Fisher. “Our team brings deep experience in CNS and MS trials, along with an integrated approach that connects strategy and execution to help deliver these complex studies. By combining scientific expertise with operational excellence, we can help bring promising new therapies closer to the patients who need them.” 

About Lucid-MS (Lucid-21-302)

Lucid-MS is an investigational, first-in-class New Chemical Entity designed to provide neuroprotection through inhibition of demyelination. Quantum BioPharma is developing Lucid-MS as a potential treatment for multiple sclerosis, with a focus on progressive forms of the disease. By targeting protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation, Lucid-MS is being developed as a potential therapeutic approach to address demyelination and neurodegenerative processes associated with MS. In preclinical models, Lucid-MS has demonstrated the ability to prevent and reverse measures of myelin degradation.

Market Opportunity and Growth Strategy

Multiple sclerosis affects approximately 2.8 million people worldwide (source: https://pmc.ncbi.nlm.nih.gov Atlas of MS, Third Edition (PMC/NCBI)), representing a significant global healthcare challenge and substantial market opportunity for innovative treatments. The MS therapeutic market is projected to exceed $38 billion by 2030 according to Grand View Research www.grandviewresearch.com.

Quantum BioPharma’s differentiated approach—targeting demyelination directly—positions Lucid-MS to address current unmet patient needs and potentially capture meaningful market share in the emerging neuroprotective segment.

About Quantum BioPharma Ltd.

Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD™ and spun out its OTC version to Unbuzzd Wellness Inc. (“Unbuzzd”) (formerly, Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.48% (as of June 30, 2026) of Unbuzzd. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

For more information visit www.quantumbiopharma.com.

Forward-Looking Information

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is generally, but not always, identified by words such as “anticipates,” “believes,” “expects,” “intends,” “plans,” “potential,” “proposes,” “estimates,” “may,” “could,” “would,” “will” and similar expressions. Forward-looking information in this news release includes, but is not limited to, statements regarding the planned Phase 2 clinical trial of Lucid-21-302 (“Lucid-MS”) in multiple sclerosis; the initiation, timing, design, conduct, enrollment, execution and completion of the Phase 2 trial; study start-up activities and related clinical research services to be provided by PPD; the Company’s ability to advance Lucid-MS following FDA clearance to proceed with the planned Phase 2 trial; the anticipated evaluation of the efficacy, safety and tolerability of Lucid-MS and of clinical and radiological endpoints; the potential neuroprotective effects, mechanism of action, therapeutic benefits and commercial potential of Lucid-MS; the Company’s ability to work with PPD, investigators and other clinical research partners; and the size, growth and potential opportunities within the multiple sclerosis therapeutics market.

Forward-looking information is based on management’s current expectations, estimates, projections, assumptions and beliefs as of the date of this news release, including assumptions regarding the Company’s ability to successfully complete study start-up activities; obtain and maintain all additional regulatory, ethics committee and institutional approvals or authorizations required to initiate and conduct the Phase 2 trial; identify, activate and retain suitable clinical trial sites and investigators; recruit and retain eligible patients within anticipated timelines; secure sufficient financing and other resources to fund the trial and the continued development of Lucid-MS; maintain adequate supplies of clinical trial material; obtain satisfactory performance from PPD and other third-party service providers; and the accuracy and applicability of preclinical findings, market data and third-party research.

Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking information. These risks and uncertainties include, among others, risks inherent in clinical development, including delays or difficulties in study start-up, site activation, patient recruitment or retention; the possibility that clinical trial results may not demonstrate the safety, efficacy or therapeutic benefit anticipated from preclinical or earlier-stage data; adverse events or other safety findings; changes in trial design, timelines, costs or regulatory requirements; the possibility that regulatory authorities may impose additional requirements, clinical holds or other restrictions; the Company’s dependence on PPD, investigators, clinical sites, manufacturers and other third parties; the availability and cost of capital; the Company’s ability to protect and maintain its intellectual property rights; competition from existing and future therapies; changes in applicable laws and regulations; and general economic, financial market and industry conditions. Drug development is inherently uncertain, and there can be no assurance that Lucid-MS will successfully complete clinical development, receive regulatory approval or, if approved, achieve commercial success.

Although the Company believes that the assumptions and expectations reflected in such forward-looking information are reasonable, there can be no assurance that they will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Actual results and future events could differ materially from those anticipated in such information.

The forward-looking information contained in this news release is made as of the date hereof. Except as required by applicable securities laws, the Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

Contacts:

Investor Relations
Robert Guzman, Investor Relations
Email:Rob@QuantumBioPharma.com
Telephone: (833) 304-0323
General Inquiries:info@QuantumBioPharma.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e240cd5f-4494-4560-80ed-5d2b856a1e14

HOUSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) — KBR (NYSE: KBR) has been awarded a project by Aramco to support the upgrade of facilities across the Marjan offshore field in the Arabian Gulf.

Under the contract, KBR will provide engineering and project execution services to support key offshore processing, gas compression, and power infrastructure facilities within the Marjan field.

The project is expected to maintain the Marjan field’s production capacity through recent field developments. It is also expected to help advance associated gas processing capabilities and strengthen long-term performance of critical offshore assets through the integration of digital technologies, automation, and power system enhancements.

“For KBR, this award reflects our long project execution relationship with Aramco,” said Jay Ibrahim, President, Sustainable Technology Solutions, KBR. “By combining our deep offshore engineering expertise with advanced automation and digital integration, we aim to help achieve Aramco’s expectations.”

KBR has supported major energy projects across the Middle East for decades, delivering engineering, technology, and program management solutions that help customers optimize performance, improve reliability, and address evolving energy infrastructure needs.

The engineering work is expected to be executed primarily from KBR’s Houston and Al-Khobar offices, leveraging the company’s decades of experience delivering complex offshore energy infrastructure projects in the Middle East and around the world.

About KBR
KBR is a global, capital-light lifecycle solutions company serving customers in high-complexity industrial, energy and infrastructure markets. Through its advisory, technical, engineering and operating expertise, KBR helps customers shape investments, reduce risk, deploy complex technologies, improve performance and deliver reliable outcomes across the asset lifecycle.

Following the planned separation of the Mission Technology Solutions business, KBR will operate as a focused standalone company with differentiated customer relationships, global execution capabilities and a capital-efficient business model. The company is positioned to benefit from long-term secular growth trends across energy security, energy transition, industrial modernization, and infrastructure investment. KBR’s 15,000 employees operate across more than 40 countries.

About Trinzic
KBR’s Mission Technology Solutions business is expected to be spun off as an independent public company in January 2027 and will then operate under the new name Trinzic. The name is inspired by the word intrinsic, reflecting the essential capabilities, deep expertise, speed and trusted performance that have defined the business for decades. Trinzic will enter the market as a global company and partner to customers supporting some of the highest priority missions across national security, human performance, global operations and space. Trinzic will launch with more than $5 billion in annual revenue, established partnerships and contracts, 18,000 employees and a global footprint.

Forward Looking Statements

The statements in this press release that are not historical statements, including statements regarding KBR’s engineering and project execution services and spin-off of the Mission Technology Solutions business, are forward-looking statements within the meaning of the federal securities laws. These statements are subject to numerous risks, uncertainties and assumptions, many of which are beyond the company’s control, that could cause actual results to differ materially from the results expressed or implied by the statements. These risks, uncertainties and assumptions include, but are not limited to, those set forth in the company’s most recently filed Annual Report on Form 10-K, any subsequent Form 10-Qs and 8-Ks and other U.S. Securities and Exchange Commission filings, which discuss some of the important risks, uncertainties and assumptions that the company has identified that may affect its business, results of operations and financial condition. Due to such risks, uncertainties and assumptions, you are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. Except as required by law, the company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

For further information, please contact:

Investors
Rachael Goldwait
Vice President, Investor Relations
713-753-5082
Investors@kbr.com

Media
Philip Ivy
Vice President, Global Communications and Marketing
713-753-3800
MediaRelations@kbr.com

HOUSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) — KBR (NYSE: KBR) has been awarded a project by Aramco to support the upgrade of facilities across the Marjan offshore field in the Arabian Gulf.

Under the contract, KBR will provide engineering and project execution services to support key offshore processing, gas compression, and power infrastructure facilities within the Marjan field.

The project is expected to maintain the Marjan field’s production capacity through recent field developments. It is also expected to help advance associated gas processing capabilities and strengthen long-term performance of critical offshore assets through the integration of digital technologies, automation, and power system enhancements.

“For KBR, this award reflects our long project execution relationship with Aramco,” said Jay Ibrahim, President, Sustainable Technology Solutions, KBR. “By combining our deep offshore engineering expertise with advanced automation and digital integration, we aim to help achieve Aramco’s expectations.”

KBR has supported major energy projects across the Middle East for decades, delivering engineering, technology, and program management solutions that help customers optimize performance, improve reliability, and address evolving energy infrastructure needs.

The engineering work is expected to be executed primarily from KBR’s Houston and Al-Khobar offices, leveraging the company’s decades of experience delivering complex offshore energy infrastructure projects in the Middle East and around the world.

About KBR
KBR is a global, capital-light lifecycle solutions company serving customers in high-complexity industrial, energy and infrastructure markets. Through its advisory, technical, engineering and operating expertise, KBR helps customers shape investments, reduce risk, deploy complex technologies, improve performance and deliver reliable outcomes across the asset lifecycle.

Following the planned separation of the Mission Technology Solutions business, KBR will operate as a focused standalone company with differentiated customer relationships, global execution capabilities and a capital-efficient business model. The company is positioned to benefit from long-term secular growth trends across energy security, energy transition, industrial modernization, and infrastructure investment. KBR’s 15,000 employees operate across more than 40 countries.

About Trinzic
KBR’s Mission Technology Solutions business is expected to be spun off as an independent public company in January 2027 and will then operate under the new name Trinzic. The name is inspired by the word intrinsic, reflecting the essential capabilities, deep expertise, speed and trusted performance that have defined the business for decades. Trinzic will enter the market as a global company and partner to customers supporting some of the highest priority missions across national security, human performance, global operations and space. Trinzic will launch with more than $5 billion in annual revenue, established partnerships and contracts, 18,000 employees and a global footprint.

Forward Looking Statements

The statements in this press release that are not historical statements, including statements regarding KBR’s engineering and project execution services and spin-off of the Mission Technology Solutions business, are forward-looking statements within the meaning of the federal securities laws. These statements are subject to numerous risks, uncertainties and assumptions, many of which are beyond the company’s control, that could cause actual results to differ materially from the results expressed or implied by the statements. These risks, uncertainties and assumptions include, but are not limited to, those set forth in the company’s most recently filed Annual Report on Form 10-K, any subsequent Form 10-Qs and 8-Ks and other U.S. Securities and Exchange Commission filings, which discuss some of the important risks, uncertainties and assumptions that the company has identified that may affect its business, results of operations and financial condition. Due to such risks, uncertainties and assumptions, you are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. Except as required by law, the company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

For further information, please contact:

Investors
Rachael Goldwait
Vice President, Investor Relations
713-753-5082
Investors@kbr.com

Media
Philip Ivy
Vice President, Global Communications and Marketing
713-753-3800
MediaRelations@kbr.com

Strategic Preferred Equity Investment and Transformational Refinancing Transactions 
to Provide Additional Financial Flexibility

Partnership with PT Danantara Investment Management and PT Energi Mega Persada Tbk
to Support Growth and Value Creation

FORT WORTH, Texas, Oct. 06, 2026 (GLOBE NEWSWIRE) — HighPeak Energy, Inc. (“HighPeak” or the “Company) (NASDAQ: HPK) today announced a comprehensive refinancing through a $450 million preferred equity investment and a new $800 million credit facility.

HighPeak has entered into an agreement with PT Danantara Investment Management (“DIM”) and PT Energi Mega Persada Tbk (IDX: ENRG) (“EMP”) (collectively, the “Investors”), pursuant to which the Investors have committed to purchase 450,000 shares of a newly created series of convertible preferred stock of the Company, to be designated as Series A 6% Perpetual Convertible Preferred Stock (the “Preferred Stock”) for total gross proceeds to the Company of approximately $450 million (the “Investment”).

In connection with the transaction, the Company has been provided with Committed Financing from Citibank, N.A. (“Citibank”) and Fifth Third Bank, N.A. (“Fifth Third”) for a new $800 million reserve-based credit facility (the “RBL”), which is expected to be completed in connection with the closing of the Investment. Together, the proceeds from the Investment, initial borrowings under the new RBL and available cash are expected to allow HighPeak to repay its existing $1.17 billion term loan in full. The Investment is expected to close during the fourth quarter of 2026 (the “Closing Date”), subject to customary closing conditions.

HighPeak’s President and Chief Executive Officer, Michael Hollis said, “Today marks a milestone for HighPeak Energy. This comprehensive refinancing will materially strengthen our balance sheet, significantly reduce our financing burden and enhance our ability to generate long-term value for shareholders. The combination of permanent capital from high-quality investors alongside a new reserve-based lending facility will enable HighPeak to retire its existing term loan and establish a much more effective capital structure.”

DIM is a sovereign fund of the Republic of Indonesia, and EMP is an Indonesia-based upstream oil and gas company. This transaction provides the Investors with exposure to HighPeak’s high-quality Midland Basin asset base, including its significant acreage position, inventory of high-quality drilling locations and infrastructure system, all situated within one of the world’s most prolific hydrocarbon basins. Under the terms of the Investment, DIM and EMP will, among other things, each appoint one director to HighPeak’s Board of Directors.
Mr. Hollis continued, “We expect that this transaction will improve our liquidity profile, materially reduce our annual interest expense, and provide us with greater financial flexibility to focus on disciplined development, free cash flow generation and continued shareholder value creation. We are particularly pleased to welcome our new capital investors, DIM and EMP, who share our long-term vision for the Company and support the direction and priorities we have established going forward. We also appreciate the support of Citibank and Fifth Third in committing to arrange and underwrite our new credit facility. These relationships provide an important foundation for future strategic collaboration as we look ahead to executing our business strategy from a stronger financial position.”

Preferred Stock Details
The Preferred Stock does not have a maturity date. Cumulative cash dividends on the Preferred Stock will be payable quarterly in arrears, on March 31, June 30, September 30 and December 31 of each year, when, as and if declared by the Company’s Board of Directors.

Each share of Preferred Stock is convertible, at the holder’s option at any time at the rate per share determined by dividing (i) the sum of (x) $1,000 per share and (y) the accrued and unpaid dividends since the immediately preceding preferred dividend by (ii) $9.50 (the “Conversion Price”).

The Preferred Stock may be redeemed by the Company on or after the third anniversary of the Closing Date upon 30 days’ notice at a redemption price equal to an amount that would result in a 10.0% IRR. The Preferred Stock will be mandatorily convertible at the option of the Company after the third anniversary of the Closing Date if the closing price of the Company’s common stock exceeds 150% of the Conversion Price for thirty out of forty consecutive market trading days.

Credit Facility Details
The proposed new senior secured facility is expected to include an initial borrowing base and elected commitments totaling $800 million. Availability under the RBL will be subject to the final borrowing base, elected commitments, outstanding borrowings, letters of credit, financial covenants and other conditions.

Advisors
Vinson & Elkins LLP is acting as legal counsel to HighPeak. Milbank LLP is acting as legal counsel to the Investors. Barclays Bank PLC is acting as financial advisor to DIM, and Citigroup Global Markets Singapore Pte. Ltd. is acting as financial advisor to EMP. Bracewell LLP is acting as legal counsel to Citibank, N.A.

About HighPeak Energy, Inc.
HighPeak Energy, Inc. is a publicly traded independent crude oil and natural gas company, headquartered in Fort Worth, Texas, focused on the acquisition, development, exploration and exploitation of unconventional crude oil and natural gas reserves in the Midland Basin in West Texas.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, with respect to the Investment, the use of proceeds therefrom, the Company’s entry into the RBL and the contemplated refinancing of the Company’s term loan. These forward-looking statements, including statements regarding the intention, completion, timing and option relating to the Investment, the RBL and the refinancing of the Company’s term loan, represent the Company’s expectations or beliefs concerning future events. These forward-looking statements are subject to risks and uncertainties related to market conditions and the satisfaction of customary closing conditions related to the Investment, the RBL and the refinancing of the Company’s term loan. There can be no assurance that the Company will be able to complete the Investment, enter into the RBL on satisfactory terms or at all or refinance the term loan. When used in this document, including any oral statements made in connection therewith, the words “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “project,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. Except as otherwise required by applicable law, the Company disclaims any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date on which they are made. The Company cautions you that these forward-looking statements are subject to all of the risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of the Company, incident to the development, production, gathering and sale of oil, natural gas and natural gas liquids.

Investor Contact:
Ryan Hightower
Executive Vice President, Business Development
817.850.9204
rhightower@highpeakenergy.com
Source: HighPeak Energy, Inc.

Strategic Preferred Equity Investment and Transformational Refinancing Transactions 
to Provide Additional Financial Flexibility

Partnership with PT Danantara Investment Management and PT Energi Mega Persada Tbk
to Support Growth and Value Creation

FORT WORTH, Texas, Oct. 06, 2026 (GLOBE NEWSWIRE) — HighPeak Energy, Inc. (“HighPeak” or the “Company) (NASDAQ: HPK) today announced a comprehensive refinancing through a $450 million preferred equity investment and a new $800 million credit facility.

HighPeak has entered into an agreement with PT Danantara Investment Management (“DIM”) and PT Energi Mega Persada Tbk (IDX: ENRG) (“EMP”) (collectively, the “Investors”), pursuant to which the Investors have committed to purchase 450,000 shares of a newly created series of convertible preferred stock of the Company, to be designated as Series A 6% Perpetual Convertible Preferred Stock (the “Preferred Stock”) for total gross proceeds to the Company of approximately $450 million (the “Investment”).

In connection with the transaction, the Company has been provided with Committed Financing from Citibank, N.A. (“Citibank”) and Fifth Third Bank, N.A. (“Fifth Third”) for a new $800 million reserve-based credit facility (the “RBL”), which is expected to be completed in connection with the closing of the Investment. Together, the proceeds from the Investment, initial borrowings under the new RBL and available cash are expected to allow HighPeak to repay its existing $1.17 billion term loan in full. The Investment is expected to close during the fourth quarter of 2026 (the “Closing Date”), subject to customary closing conditions.

HighPeak’s President and Chief Executive Officer, Michael Hollis said, “Today marks a milestone for HighPeak Energy. This comprehensive refinancing will materially strengthen our balance sheet, significantly reduce our financing burden and enhance our ability to generate long-term value for shareholders. The combination of permanent capital from high-quality investors alongside a new reserve-based lending facility will enable HighPeak to retire its existing term loan and establish a much more effective capital structure.”

DIM is a sovereign fund of the Republic of Indonesia, and EMP is an Indonesia-based upstream oil and gas company. This transaction provides the Investors with exposure to HighPeak’s high-quality Midland Basin asset base, including its significant acreage position, inventory of high-quality drilling locations and infrastructure system, all situated within one of the world’s most prolific hydrocarbon basins. Under the terms of the Investment, DIM and EMP will, among other things, each appoint one director to HighPeak’s Board of Directors.
Mr. Hollis continued, “We expect that this transaction will improve our liquidity profile, materially reduce our annual interest expense, and provide us with greater financial flexibility to focus on disciplined development, free cash flow generation and continued shareholder value creation. We are particularly pleased to welcome our new capital investors, DIM and EMP, who share our long-term vision for the Company and support the direction and priorities we have established going forward. We also appreciate the support of Citibank and Fifth Third in committing to arrange and underwrite our new credit facility. These relationships provide an important foundation for future strategic collaboration as we look ahead to executing our business strategy from a stronger financial position.”

Preferred Stock Details
The Preferred Stock does not have a maturity date. Cumulative cash dividends on the Preferred Stock will be payable quarterly in arrears, on March 31, June 30, September 30 and December 31 of each year, when, as and if declared by the Company’s Board of Directors.

Each share of Preferred Stock is convertible, at the holder’s option at any time at the rate per share determined by dividing (i) the sum of (x) $1,000 per share and (y) the accrued and unpaid dividends since the immediately preceding preferred dividend by (ii) $9.50 (the “Conversion Price”).

The Preferred Stock may be redeemed by the Company on or after the third anniversary of the Closing Date upon 30 days’ notice at a redemption price equal to an amount that would result in a 10.0% IRR. The Preferred Stock will be mandatorily convertible at the option of the Company after the third anniversary of the Closing Date if the closing price of the Company’s common stock exceeds 150% of the Conversion Price for thirty out of forty consecutive market trading days.

Credit Facility Details
The proposed new senior secured facility is expected to include an initial borrowing base and elected commitments totaling $800 million. Availability under the RBL will be subject to the final borrowing base, elected commitments, outstanding borrowings, letters of credit, financial covenants and other conditions.

Advisors
Vinson & Elkins LLP is acting as legal counsel to HighPeak. Milbank LLP is acting as legal counsel to the Investors. Barclays Bank PLC is acting as financial advisor to DIM, and Citigroup Global Markets Singapore Pte. Ltd. is acting as financial advisor to EMP. Bracewell LLP is acting as legal counsel to Citibank, N.A.

About HighPeak Energy, Inc.
HighPeak Energy, Inc. is a publicly traded independent crude oil and natural gas company, headquartered in Fort Worth, Texas, focused on the acquisition, development, exploration and exploitation of unconventional crude oil and natural gas reserves in the Midland Basin in West Texas.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, with respect to the Investment, the use of proceeds therefrom, the Company’s entry into the RBL and the contemplated refinancing of the Company’s term loan. These forward-looking statements, including statements regarding the intention, completion, timing and option relating to the Investment, the RBL and the refinancing of the Company’s term loan, represent the Company’s expectations or beliefs concerning future events. These forward-looking statements are subject to risks and uncertainties related to market conditions and the satisfaction of customary closing conditions related to the Investment, the RBL and the refinancing of the Company’s term loan. There can be no assurance that the Company will be able to complete the Investment, enter into the RBL on satisfactory terms or at all or refinance the term loan. When used in this document, including any oral statements made in connection therewith, the words “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “project,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. Except as otherwise required by applicable law, the Company disclaims any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date on which they are made. The Company cautions you that these forward-looking statements are subject to all of the risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of the Company, incident to the development, production, gathering and sale of oil, natural gas and natural gas liquids.

Investor Contact:
Ryan Hightower
Executive Vice President, Business Development
817.850.9204
rhightower@highpeakenergy.com
Source: HighPeak Energy, Inc.